Literature DB >> 17767465

Health-related quality of life in patients with non-alcoholic fatty liver disease.

A A Dan1, J B Kallman, A Wheeler, Z Younoszai, R Collantes, S Bondini, L Gerber, Z M Younossi.   

Abstract

BACKGROUND: The relative impact of non-alcoholic fatty liver disease (NAFLD) on health-related quality of life (HRQL) compared to other chronic liver diseases has not been fully explored. AIM: To compare the domain scores of the 29-item Chronic Liver Disease Questionnaire (CLDQ) for patients with NAFLD to those with chronic hepatitis B and chronic hepatitis C.
METHODS: A HRQL questionnaire, CLDQ, was routinely administered to patients attending a liver clinic. Additional clinical and laboratory data were obtained on patients with NAFLD, chronic hepatitis B, and chronic hepatitis C from our quality of life database. Scores for each of the six CLDQ domains were compared using one-way anova and multiple regression.
RESULTS: Complete data were available for 237 patients. NAFLD patients scored lowest on multiple CLDQ domains. Based on the bivariate data, NAFLD patients have the poorest HRQL, followed by chronic hepatitis C and chronic hepatitis B patients. Multivariate analysis showed that some specific domain score correlations remained significant for NAFLD diagnosis, cirrhosis, gender, and body mass index.
CONCLUSION: NAFLD patients had significantly lower quality of life scores compared with patients with hepatitis B or hepatitis C on multiple CLDQ domains, suggesting that HRQL was severely impaired in patients with NAFLD.

Entities:  

Mesh:

Year:  2007        PMID: 17767465     DOI: 10.1111/j.1365-2036.2007.03426.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  40 in total

1.  Metabolic Syndrome Is Associated with Health-Related Quality of Life in Suspected Patients with Nonalcoholic Steatohepatitis.

Authors:  Ali Gholami; Farhad Zamani; Bayan Hosseini; Rahim Sharafkhani; Mansooreh Maadi; Zahra Moosavi Jahromi; Maryam Khazaee-Pool; Masoudreza Sohrabi
Journal:  Med Princ Pract       Date:  2018-02-05       Impact factor: 1.927

2.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

3.  PROMIS computerised adaptive tests are dynamic instruments to measure health-related quality of life in patients with cirrhosis.

Authors:  J S Bajaj; L R Thacker; J B Wade; A J Sanyal; D M Heuman; R K Sterling; D P Gibson; R T Stravitz; P Puri; M Fuchs; V Luketic; N Noble; M White; D Bell; D A Revicki
Journal:  Aliment Pharmacol Ther       Date:  2011-09-19       Impact factor: 8.171

4.  A simple Indian diabetes risk score could help identify nondiabetic individuals at high risk of non-alcoholic fatty liver disease (CURES-117).

Authors:  Viknesh Prabu Anbalagan; Vijayachandrika Venkataraman; Mamilla Vamsi; Mohan Deepa; Viswanathan Mohan
Journal:  J Diabetes Sci Technol       Date:  2012-11-01

5.  Weight loss results in significant improvements in quality of life for patients with nonalcoholic fatty liver disease: A prospective cohort study.

Authors:  Elliot B Tapper; Michelle Lai
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

6.  Outcomes of Palliative Care Consultations for Hospitalized Patients With Liver Disease.

Authors:  Nneka N Ufere; David L O'Riordan; Kara E Bischoff; Angela K Marks; Nwamaka Eneanya; Raymond T Chung; Vicki Jackson; Steven Z Pantilat; Areej El-Jawahri
Journal:  J Pain Symptom Manage       Date:  2019-07-19       Impact factor: 3.612

7.  Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.

Authors:  Arun J Sanyal; Scott L Friedman; Arthur J McCullough; Lara Dimick-Santos
Journal:  Hepatology       Date:  2015-03-19       Impact factor: 17.425

Review 8.  Quality of life in cirrhosis.

Authors:  Anthony Loria; Carey Escheik; N Lynn Gerber; Zobair M Younossi
Journal:  Curr Gastroenterol Rep       Date:  2013-01

9.  Nonalcoholic fatty liver disease: Disease and comorbidity--effects on quality of life.

Authors:  Giulio Marchesini; Giampaolo Bianchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09       Impact factor: 46.802

10.  Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease.

Authors:  K D Kistler; J Molleston; A Unalp; S H Abrams; C Behling; J B Schwimmer
Journal:  Aliment Pharmacol Ther       Date:  2009-10-23       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.